Discover and Validate Ultrasensitive Fluid, Imaging and Digital Measures to Enable Earlier Intervention, Drive Precision and De-Risk CNS Drug Development Europe is rapidly becoming a hub for next-generation CNS biomarker innovation. Landmark approvals of the first Alzheimer's blood tests, rapid advances in ultrasensitive biomarker technologies, and growing investment across European biopharma are accelerating the shift towards precision-driven drug development. However, despite this momentum, more than 80% of late-stage CNS clinical trials still fail to meet their primary endpoints, highlighting the urgent need for biomarkers that can improve patient stratification, demonstrate target engagement and generate earlier signals of efficacy. The Novel CNS Biomarkers Summit Europe is the only European meeting dedicated exclusively to advancing fluid, imaging and digital biomarkers for CNS drug development. Join 60+ biomarker, translational medicine, neuroscience, precision medicine, bioanalytical, multi-omics, and clinical development leaders from leading to explore how next-generation biomarkers are being discovered, validated and translated across Alzheimer's disease, Parkinson's disease, ALS, epilepsy, schizophrenia, MSA and other CNS indications Across three days, discover how industry leaders are implementing α-synuclein seed amplification assays, digital cognitive and EEG biomarkers, novel blood-based biomarkers, toxic oligomer assays and multimodal biomarker strategies to strengthen decision-making from early discovery through clinical development. Gain practical insights into harmonising biomarker assays, reducing reliance on lumbar puncture, generating regulatory-ready biomarker data and implementing scalable biomarker programmes that are accelerating the development of CNS therapeutics.

Description supplied by the event organiser.